secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001104659-24-030772
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee releases APG777 Phase 1 data in web presentation; no specific results in 8-K
--------------------------------------------------------------------------------

- Phase 1 first-in-human data for APG777 posted to company website on March 5, 2024.
- Presentation covers safety, pharmacokinetics, and biomarker data from initial cohort.
- No numerical efficacy or safety figures are disclosed in the 8-K filing itself.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924030772/0001104659-24-030772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924030772/tm247826d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-030772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer